C4 Therapeutics reports 2022 EPS ($2.62), consensus ($2.57)

Reports 2022 revenue $31.096M, consensus $39.8M. "2022 was a year of execution that has laid the groundwork for 2023 as we work to progress three clinical programs, with a fourth expected to enter the clinic by year end," said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. "With cash runway through the end of 2024, we look forward to having two clinical readouts in the second half of the year, which have the potential to validate our TORPEDO platform to develop both BiDAC and MonoDAC degraders for patients with difficult-to-treat diseases."